Log in to search using one of your social media accounts:

 

Life- and Eye-Saving New Treatments for Uveal Melanoma Life- and Eye-Saving New Treatments for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 15, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Breakthrough Treatments Arriving for Uveal Melanoma Breakthrough Treatments Arriving for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye-Saving New Treatment Options for Uveal Melanoma Eye-Saving New Treatment Options for Uveal Melanoma
Gene testing and immunotherapy have opened the door to treatments that could save the eyesight and the lives of people with uveal melanoma.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 14, 2017 Category: Pathology Tags: Ophthalmology News Source Type: news

Genetic Glitches in Uveal Melanoma: Ophthalmology Times
(MedPage Today) -- Also, the limits of anti-VEGF therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 22, 2017 Category: Hematology Source Type: news

Georgia State's Inlighta Biosciences gets $2 million grant to develop enhanced MRI contrast agents
(Georgia State University) A local start-up, life sciences company founded by Dr. Jenny Yang, Regents' Professor of Biochemistry at Georgia State University, has received a $2 million federal grant to develop improved magnetic resonance imaging (MRI) contrast agents for the early detection of liver cancers and other cancers, such as uveal melanoma or eye cancer, that have metastasized to the liver. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 24, 2017 Category: International Medicine & Public Health Source Type: news

Adoptive T-Cell Therapy Induced Response in Metastatic Uveal Melanoma
More than one-third of patients with metastatic uveal melanoma had objective tumor regression when treated with adoptive transfer of autologous tumor-infiltrating lymphocytes. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

Emerging Therapies for Uveal Melanoma: Ophthalmology Times
(MedPage Today) -- Also: avoiding ruptures during deep anterior lamellar keratoplasty (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 2, 2017 Category: American Health Source Type: news

Metastatic Disease From Uveal Melanoma Metastatic Disease From Uveal Melanoma
What treatment options are available for patients who develop metastatic disease from this type of ocular melanoma?The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Increased eye cancer risk linked to pigmentation genes that dictate eye color
New research links specific inherited genetic differences to an increased risk for eye (uveal) melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. scientists report the first evidence of a strong association between genes linked to eye color and development of uveal melanoma. Reported data suggests that inherited genetic factors associated with eye and skin pigmentation could increase a person's risk for uveal melanoma. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 19, 2016 Category: Science Source Type: news

Increased eye cancer risk linked to pigmentation genes that dictate eye color
(Ohio State University Wexner Medical Center) New research links specific inherited genetic differences to an increased risk for eye (uveal) melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. scientists report the first evidence of a strong association between genes linked to eye color and development of uveal melanoma. Reported data suggests that inherited genetic factors associated with eye and skin pigmentation could increase a person's risk for uveal melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2016 Category: Global & Universal Source Type: news

European H2020 grant to fight eye cancer for the next 5 years
(JLM&A, SA ) UM Cure 2020 is a new European Consortium to foster research on metastatic uveal melanoma and identify new treatments for this serious disease.Under the coordination of Institut Curie in Paris, the Consortium involving 12 partners has received 6 million euros of funding from the European Union's Horizon 2020 research and innovation program to identify new therapeutic approaches to treat metastatic uveal melanoma in a five-year project. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2016 Category: Global & Universal Source Type: news

[Editors' Choice] One target to quench many
Inhibiting the GTPase ARF6 chokes the diverse output of mutant Gαq proteins in uveal melanoma. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 29, 2016 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news

Researchers Make Progress in Unraveling Uveal MelanomaResearchers Make Progress in Unraveling Uveal Melanoma
Two studies from the University of Miami Miller School of Medicine shed light on physiological and genetic factors associated with uveal melanoma (UM). Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

UK’s Immunocore begins Phase I trial of uveal melanoma drug IMCgp100
UK-based biotechnology company Immunocore has started its Phase I monotherapy trial of its lead programme, IMCgp100, to treat patients with uveal melanoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 29, 2016 Category: Pharmaceuticals Source Type: news

New biomarker identifies uveal melanoma patients at high risk for metastasis
(University of Miami Miller School of Medicine) A study by J. William Harbour, M.D., associate director for Basic Research and leader of the Eye Cancer Site Disease Group at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and colleagues published today in Clinical Cancer Research details the discovery of a biomarker that puts patients at a higher risk for metastasis of uveal melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2016 Category: Cancer & Oncology Source Type: news

Gratitude for Dr. Oliver Sacks' Insights at the End of Life
Just as he shed light on the human mind and soul over the course of his celebrated career, the neurologist and writer Dr. Oliver Sacks gave us profound insights in his final year into the most universal of human experiences: dying. One year ago, diagnosed with metastasized uveal melanoma, he began to chronicle his thoughts, feelings, priorities and vivid observations as he lived what would become his final months. "I have been able to see my life as from a great altitude, as a sort of landscape, and with a deepening sense of the connection of all its parts," he writes in "My Own Life," an essay in his ...
Source: Healthy Living - The Huffington Post - February 2, 2016 Category: Consumer Health News Source Type: news

New Strategies but Modest Benefit in Uveal MelanomaNew Strategies but Modest Benefit in Uveal Melanoma
New therapies being tried in uveual melanoma include combination everolimus, pasireotide long-acting release, and the MEK inhibitor trametinib. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 23, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

All Was Well -- Then My Fiancee Got Cancer
Photo caption: Brent and Emily Stoller on their wedding day in Rancho Mirage, CA. Photo credit: Amy & Stuart Photography Which band do we want? What color should the groomsmen wear? Can our rehearsal dinner video montage be made to resemble A-Ha's "Take on Me"? For my fiancée, Emily, and me, the planning process for our wedding was routine. Until 32 days before "I do," when a new entry was Sharpie'd onto our to-do list: Cancer. ***** These stories all start the same. April 7, 2015 dawned like any other Tuesday. Emily was at the ophthalmologist because she'd been experiencing blurriness, whic...
Source: Healthy Living - The Huffington Post - September 30, 2015 Category: Consumer Health News Source Type: news

Arteries better than veins for liquid biopsy
(Thomas Jefferson University) Arteries contain higher numbers of circulating tumor cells than veins in uveal melanoma patients, raising a concern for standard technique for detection of tumor cells in the blood. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2015 Category: Cancer & Oncology Source Type: news

Aura Biosciences's AU-011 drug receives FDA orphan drug status for uveal melanoma
Biotech firm Aura Biosciences has received orphan drug designation from the US Food and Drug Administration (FDA) for its drug, AU-011, to treat patients with uveal melanoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 21, 2015 Category: Pharmaceuticals Source Type: news

Melanoma-Related Mortality Risk Persists Decades After Uveal TreatmentMelanoma-Related Mortality Risk Persists Decades After Uveal Treatment
The risk of melanoma-related mortality persists for decades after treatment of uveal melanoma with proton beam therapy, according to results from a retrospective study. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 29, 2015 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Uveal Melanoma: Evidence for Adjuvant TherapyUveal Melanoma: Evidence for Adjuvant Therapy
This review provides a summary of the evidence for the use of adjuvant therapy in treatment of uveal melanoma. International Ophthalmology Clinics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

NICE approves creation of guidelines on rare form of cancer
Funded by the charity Melanoma Focus, and produced by an independent guideline development group, the process behind new guidelines on uveal melanoma is the latest to be accredited by NICE. Uveal melanoma is a very rare condition, but is also the most common type of melanoma that affects the eye. It occurs along the uveal tract, which affects the choroid, ciliary body and iris, and can lead to loss of sight or of the eye itself. More ..... (Source: NHS Networks)
Source: NHS Networks - January 14, 2015 Category: UK Health Authors: Maria Axford Source Type: news

Ipilimumab in Uveal Melanoma: Long-Lasting Responses in 25%Ipilimumab in Uveal Melanoma: Long-Lasting Responses in 25%
The first trial of ipilimumab in patients with uveal melanoma has shown some long-lasting responses in a patient population with poor prognosis. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 3, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye
(Mayo Clinic) One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called tumor necrosis factor inhibitors. They act by dampening part of the immune system called tumor necrosis factor. In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of eye cancer, uveal melanoma. Mayo Clinic researchers make the case and alert physicians in an article in Mayo Clinic Proceedings (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2014 Category: Global & Universal Source Type: news

Treating Uveal Melanomas Effectively With LessTreating Uveal Melanomas Effectively With Less
Could 'less is more' be a better approach to the management of this rare but devastating condition? Medscape Optometry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2014 Category: Consumer Health News Tags: Viewpoint Source Type: news

Drug shows promise for the first time against metastatic melanoma of the eye
For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye. Results from a multicenter clinical trial show that a new drug called selumetinib increases progression-free survival, the length of time during and after treatment that a patient with metastases lives with the disease without it progressing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 19, 2014 Category: Science Source Type: news

Drug shows promise for the first time against metastatic melanoma of the eye
(Columbia University Medical Center) For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 19, 2014 Category: Biology Source Type: news

Selumetinib Yields Modest Benefits in Rare Eye CancerSelumetinib Yields Modest Benefits in Rare Eye Cancer
The first randomized controlled trial of the MEK inhibitor selumetinib finds modest improvement in clinical outcomes of advanced uveal melanoma but high rates of adverse effects. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 17, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study compares survival for treatments of uncommon eye cancer
(The JAMA Network Journals) In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2014 Category: Cancer & Oncology Source Type: news

Animal Trials Show Promise for Treating Eye Cancer
Researchers target genetic mutations common among uveal melanoma patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 29, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Nursing, Oncology, Ophthalmology, Research, News, Source Type: news

Melanoma of the eye caused by two gene mutations
A therapeutic target for treating the most common form of eye cancer in adults has been identified by researchers. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug. The researchers looked specifically at uveal melanoma. Uveal collectively refers to parts of the eye, notably the iris, that contain pigment cells. As with melanoma skin cancer, uveal melanoma is a malignancy of these melanin-producing cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 29, 2014 Category: Science Source Type: news

For Ocular Melanoma Mets to Liver, Fotemustine DisappointsFor Ocular Melanoma Mets to Liver, Fotemustine Disappoints
For patients with uveal melanoma (UM) metastases in the liver, response rates and progression-free survival are only slightly better if fotemustine is given through the hepatic artery rather then intravenously, new data show. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 27, 2014 Category: Opthalmology Tags: Hematology-Oncology News Source Type: news

Surgical Management of Posterior Uveal MelanomaSurgical Management of Posterior Uveal Melanoma
Uveal melanoma is the most common primary malignancy of the eye in adults and affects approximately 4 people per million in the US each year. Find out how globe-salvaging treatment and more are improving outcomes. Expert Review of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Castle Biosciences launches tissue repository for eye cancer patients
Castle Biosciences Inc. has announced the availability of a tumor tissue repository for patients whose tumors are being tested with the Company's gene test for uveal, or ocular, melanoma. Patients will now have the option of storing an additional sample of their tumor free of charge for up to five years, and will be able to access it to take advantage of future developments in the disease. Castle Biosciences would provide the samples to third parties only with permission of the patient for legitimate research, treatment guidance or diagnostic purposes... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 2, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Palladium-103 Radiation Effective for Small Choroidal MelanomaPalladium-103 Radiation Effective for Small Choroidal Melanoma
Palladium-103 plaque radiation therapy was effective for treating small choroidal melanomas in a retrospective study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In Metastatic Uveal Melanoma, New Drug Improves Progression-Free Survival, Shrinks Tumors
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The findings are potentially practice-changing for a historically "untreatable disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

First Drug To Help Melanoma Of The Eye
AstraZeneca's experimental drug, selumetinib, is the first targeted medication to show a significant clinical benefit for patients with melanoma of the eye (metastatic uveal melanoma), researchers from the Memorial Sloan-Kettering Cancer Center explained at the 49th annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago, Illinois. The scientists say that their findings will probably change clinical practice for patients with metastatic uveal melanoma, which to date has been an "untreatable disease"... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 2, 2013 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

ASCO: Rare Eye Cancer Yields to Targeted Drug
CHICAGO (MedPage Today) -- The novel kinase inhibitor selumetinib may be the first treatment to shrink advanced uveal melanoma, based on phase II trial results. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2013 Category: Hematology Source Type: news

Breakthrough in Rare Cancer: First Drug Works Uveal MelanomaBreakthrough in Rare Cancer: First Drug Works Uveal Melanoma
For the first time, a systemic therapy has shown clinical activity in a rare eye cancer, metastatic uveal melanoma, for which there is no standard treatment. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Breakthrough in Rare Eye Cancer: First Drug That WorksBreakthrough in Rare Eye Cancer: First Drug That Works
For the first time, a systemic therapy has shown clinical activity in a rare eye cancer, metastatic uveal melanoma, for which there is no standard treatment. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New drug improves progression-free survival, shrinks tumors in rare cancer for first time
(Memorial Sloan-Kettering Cancer Center) The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2013 Category: Global & Universal Source Type: news

Detecting Hepatic Metastases From High-risk Uveal MelanomaDetecting Hepatic Metastases From High-risk Uveal Melanoma
Is MRI an effective tool for clinicians to diagnose hepatic metastases that can arise from uveal melanomas? This new study investigates. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Intensive Surveillance for Choroidal Melanoma MetastasisIntensive Surveillance for Choroidal Melanoma Metastasis
Aggressive CT or PET/CT surveillance protocols confer a significant risk of radiation-induced cancer in patients being monitored for metastasis from primary choroidal melanoma. Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 17, 2013 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Aggressive surveillance questionable for eye melanoma recurrence
Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 14, 2013 Category: Cancer & Oncology Source Type: news